How to buy VIVUS stock

VIVUS Inc is a biotechnology business based in the US. VIVUS shares (VVUS) are listed on the NASDAQ and all prices are listed in US Dollars. VIVUS employs 59 staff and has a trailing 12-month revenue of around 0.00.

Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

VIVUS stock price (NASDAQ: VVUS)

Use our graph to track the performance of VVUS stocks over time.

VIVUS shares at a glance

• Key figures

Information last updated 2021-01-13.

52-week range	$0.00 - $0.00
50-day moving average more info button	$0.12
200-day moving average more info button	$0.30
Wall St. target price	$1.75
PE ratio more info button	N/A
Dividend yield more info button	N/A (0%)
Earnings per share (TTM) more info button	$-2.60

Buy VIVUS shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy VIVUS stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is VIVUS stock undervalued or overvalued?

Valuing VIVUS stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of VIVUS's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

VIVUS's EBITDA

VIVUS's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $5.8 million.

The EBITDA is a measure of a VIVUS's overall financial performance and is widely used to measure a its profitability.

VIVUS financials

Revenue TTM	$73.2 million
Gross profit TTM	$43.8 million
Return on assets TTM	-2.2%
Return on equity TTM	0%
Profit margin	-39.28%
Book value	$-4.93
Market capitalisation more info button	$8.3 million

TTM: trailing 12 months

VIVUS share dividends

We're not expecting VIVUS to pay a dividend over the next 12 months.

Have VIVUS's shares ever split?

VIVUS's shares were split on a 1:10 basis on 10 September 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your VIVUS shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for VIVUS shares which in turn could have impacted VIVUS's share price.

VIVUS share price volatility

Over the last 12 months, VIVUS's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while VIVUS's is -0.8493. This would suggest that VIVUS's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, VIVUS has bucked the trend.

VIVUS overview

VIVUS, Inc. operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol. It also provides PANCREAZE to treat exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatic cancer or other conditions; and STENDRA/SPEDRA, an oral phosphodiesterase type 5 inhibitor for erectile dysfunction. In addition, the company is developing Qsymia, which has completed Phase II clinical study for treating various diseases, including obstructive sleep apnea, diabetes, nonalcoholic steatohepatitis, and bariatric surgery; and VI-0106 that has completed Phase IIa study to treat patients with pulmonary arterial hypertension. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation; Menarini Group; Sanofi; Metuchen Pharmaceuticals, LLC; Selten Pharma, Inc. ; and Alvogen Malta Operations (ROW) Ltd.

Frequently asked questions

What percentage of VIVUS is owned by insiders or institutions?
Currently 7.089% of VIVUS shares are held by insiders and 19.065% by institutions. How many people work for VIVUS?
Latest data suggests 59 work at VIVUS. When does the fiscal year end for VIVUS?
VIVUS's fiscal year ends in December. Where is VIVUS based?
VIVUS's address is: 900 East Hamilton Avenue, Campbell, CA, United States, 95008 What is VIVUS's ISIN number?
VIVUS's international securities identification number is: US9285513084 What is VIVUS's CUSIP number?
VIVUS's Committee on Uniform Securities Identification Procedures number is: 928551100